Sai Parenterals Limited shareholders approved all 12 resolutions at its 25th Annual General Meeting on September 10, 2026. The meeting, conducted via video conference, saw high engagement from institutional and public investors.

The agenda included routine matters such as the adoption of audited financial statements for FY26 and the appointment of secretarial auditors. More significant corporate actions included the reappointment of key board members and the ratification of employee stock option plans.

Board and Management Changes

Shareholders approved the reappointment of Anil Kumar Karusala as a director by rotation and as Managing Director through special resolutions. Mrs. Vijitha Gorrepati was also reappointed as Whole-Time Director. Additionally, Mr. Kunal Kakumanu was appointed as an Executive Director.

All three appointments received overwhelming support. The resolution to appoint Mr. Kakumanu saw 99.91% votes in favour, while the reappointments of Mr. Karusala and Mrs. Gorrepati garnered nearly unanimous approval from the promoter group and public institutions.

Employee Stock Option Plan Ratification

A key focus of the meeting was the ratification of the Sai Parenterals Limited Employee Stock Option Plan 2025 (ESOP Scheme - 2025). Shareholders approved both the main scheme and its extension to subsidiary companies via special resolutions.

While the resolutions passed with requisite majorities, they faced notable opposition from institutional investors. Approximately 26.3% of votes polled by public institutions were cast against the ESOP ratification, compared to less than 0.06% dissent from non-institutional public shareholders.

Related-Party Transactions and IPO Proceeds

The AGM also addressed material related-party transactions (RPTs). Shareholders approved a loan to Sai Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals Pty. Limited in Australia. This ordinary resolution received 90.41% support among voting shareholders.

Another RPT involving ongoing transactions with Noumed Pharmaceuticals for FY27 was approved with 99.96% support. Promoter group members abstained from voting on these related-party matters as per regulatory requirements.

Furthermore, shareholders approved a variation in the objects and terms of utilisation of IPO proceeds, extending the timeline for capacity expansion and R&D centre establishment as originally disclosed in the March 2026 prospectus.

Voting Participation Analysis

Promoter group participation stood at 100%, with all shares held voting in favour of non-conflicted resolutions. Institutional investors showed strong engagement with an 84.97% participation rate. Retail and non-institutional public shareholders participated at a lower rate of 40.68%.

What the Numbers Show

The divergence in voting patterns highlights distinct investor priorities. While promoter and retail shareholders uniformly supported management proposals, institutional investors exercised significant dissent on governance-sensitive items. The 26.3% rejection rate from institutions on the ESOP scheme contrasts sharply with the near-unanimous support for operational RPTs, suggesting institutional scrutiny focused primarily on equity dilution rather than strategic funding structures.

Sai Parenteral'S has secured a confirmed Rs 204 crore work order for the renewal of an OTC medicines supply agreement with one of Australia's leading pharmacy chains. The contract spans three years and covers manufacturing, sourcing, regulatory compliance, and nationwide distribution.

WHAT HAPPENED

Sai Parenteral received a confirmed work order valued at Rs 204 crore from one of Australia's leading pharmacy chains. This is a renewal of the existing OTC Medicines Supply Agreement, featuring an expanded product portfolio. The contract term is three years, covering end-to-end value chain management including manufacturing, TGA registrations, warehousing, quality assurance, and distribution. The filing was disclosed to exchanges on 25 August 2026.

ORDER IN FINANCIAL CONTEXT

The Rs 204 crore order value is approximately 1.52 times the company's average quarterly revenue of Rs 134.35 crore. When added to previous wins, the total disclosed order book stands at Rs 5613 crore (sum of the 7 orders disclosed across the last 3 fiscal quarters shown in the table below). This backlog represents 41.78 quarters of average quarterly revenue, indicating a substantial pipeline relative to current sales scale. The book-to-bill ratio is extremely elevated, suggesting that execution capacity and working capital deployment will be the primary constraints on near-term revenue realization rather than order acquisition.

COMPANY ORDER TRACK RECORD

Order inflow velocity has remained stable at high levels over the last two reported quarters. Q2FY27 saw Rs 2804.00 crore in inflows, closely mirroring the Rs 2809.00 crore recorded in Q1FY27. The current Rs 204 crore order is smaller than the mega-contracts (Rs 1300 crore each) signed earlier in the period but consistent with the company's strategy of securing multiple large-scale agreements with key international partners. The client base remains heavily concentrated on Australian pharmacy networks.

EXECUTION AND REVENUE QUALITY

The company reported consolidated revenue of Rs 182.40 crore in Q1FY27, up from Rs 99.30 crore in Q3FY26, though down from Rs 200.80 crore in Q4FY26. Net profit stood at Rs 7.90 crore in Q1FY27, recovering from a net loss of Rs 6.70 crore in Q3FY26. Operating profit margin (OPM) improved to 13.16% in Q1FY27 from negative 3.70% in Q3FY26, but remained slightly below the 13.18% recorded in Q4FY26. This volatility suggests ongoing margin pressure or one-off costs affecting profitability despite strong top-line growth.

REVENUE GROWTH - ORDER WINS TRANSLATING TO REVENUE

As Sai Parenteral has sustained order wins, with significant inflows in recent quarters, its annual revenue has grown from Rs 163.70 crore in FY25 to Rs 381.00 crore in FY26, representing a YoY growth of +132.7% based on the latest annual data. This sharp acceleration in revenue aligns with the ramp-up of large international contracts, although net profit declined by 51.4% in the same period, highlighting a divergence between top-line expansion and bottom-line retention.

WORKING CAPITAL AND EXECUTION CAPACITY

The company maintains a current ratio of 1.44x, providing adequate short-term liquidity to manage operations. Total Liabilities/Equity stands at 1.90x, which includes trade payables and other non-debt liabilities alongside any borrowings. Operating cashflow improved significantly to Rs 93.10 crore in FY26 from Rs 33.20 crore in FY25, while free cashflow was positive at Rs 27.60 crore. This positive cash conversion indicates that the company is effectively collecting receivables and managing working capital cycles, which is critical for funding the execution of its large order book without excessive external financing.

WHAT TO WATCH

• Execution rate: Monitor whether quarterly revenue can sustainably scale to match the Rs 5613 crore backlog without diluting margins further.
• Margin trajectory: Watch for stabilization of OPM above 13% as new contracts execute, given the recent volatility including a loss-making quarter.
• Client concentration: A significant portion of the disclosed order book comes from Australian pharmacy networks; any disruption in these relationships would impact the backlog materially.
• Working capital efficiency: Ensure that the rapid revenue growth does not stretch receivables days, potentially turning positive operating cashflows negative.

KEY OBSERVATIONS

• Margin stress: Net loss of Rs 6.70 crore in Q3FY26; execution stress visible in quarterly data, though recovered in subsequent quarters.
• Valuation check (as of 25 Aug 2026): P/E of 112.6x against ROCE of 28.92%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Backlog signal: Book-to-bill of 41.78x. At this level, execution capacity becomes the binding constraint.
• Promoter holding: Moved from 61.23% to 51.16% in Q1FY27, a 10.07 pp change.